StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
DAVI

DAVION HEALTHCARE PLC

DAVI Surgical & Medical Instruments & Apparatus EDGAR ↗
—
—

Key statistics

from XBRL data in SEC filings
Market cap ⓘ
—
Revenue (TTM) ⓘ
—
Net income (TTM) ⓘ
—
EPS (TTM) ⓘ
—
P/E ratio ⓘ
—
Dividend yield ⓘ
—
Free cash flow ⓘ
—
Cash ⓘ
—
Total assets ⓘ
—
Gross margin ⓘ
—
52-week range ⓘ
—

AI briefing

from the latest 10-K, 10-Q and 8-K events

Davion Healthcare Plc is an Ireland-based medical devices company listed on NASDAQ, focused on surgical and medical instruments.

What they do

The company operates in the surgical and medical instruments sector. Its principal executive offices are in Cork, Ireland, and it has a U.S. agent for service in Bethesda, Maryland. The company's business overview is detailed in Item 4 of its 20-F filing.

Revenue drivers

  • Surgical instruments — Primary product line, but no revenue figures provided in the excerpt.
  • Medical apparatus — Related product category, no specific revenue breakdown available.

Recent performance

The filing is for the fiscal year ended December 31, 2025. No financial results are disclosed in the provided excerpts. The company is a non-accelerated filer and an emerging growth company.

Strategy

The filing is an amendment solely to correct a typographical error in the auditor's report date. No strategic direction is described in the excerpts.

Risks

  • Limited operating history — As an emerging growth company, it may have less operating history and resources than larger competitors.
  • Regulatory approval risk — Medical device products may require regulatory clearances that are uncertain and costly.
  • Dependence on international operations — Based in Ireland with U.S. listing, subject to cross-border regulatory and tax complexities.
  • No revenue visibility — Excerpts provide no financial data, making it difficult to assess commercial traction.

Outlook

Management does not provide forward-looking statements in the excerpt. The amendment filing suggests a focus on compliance and reporting accuracy.